Table 2.
Demographic, clinical characteristics, and disease severity according to main etiological group in the epidemic season 2022–2023
|
RSV+ (N = 205) |
RSV– (N = 83) |
P-value | |
|---|---|---|---|
| Male, N (%) | 105 (51.2) | 50 (60.2) | 0.164 |
| Age, Days (IQR) | 65.1 (43.4–116.4) | 63.1 (42.9–133.6) | 0.927 |
| Preterm Birth, N (%) | 23 (11.2) | 9 (10.8) | 0.926 |
| Palivizumab, N (%) | 3 (1.5) | 5 (6.0) | 0.033 |
| Birth weight, grams (IQR) | 3330 (2900–3580) | 3300 (3040–3555) | 0.933 |
| Breastfeeding, N (%) | 158 (77.4) | 64 (81.0) | 0.939 |
| Siblings, N (%) | 132 (68.4) | 55 (68.7) | 0.954 |
| Comorbidities | 8 (3.9) | 8 (9.8) | 0.052 |
| Los, Days (IQR) | 4.9 (3.9–6.9) | 2.9 (2.9–4.9) | < 0.001 |
| Need for O2, N (%) | 186 (90.7) | 51 (61.44) | < 0.001 |
| LOO, Days (IQR) | 4 (2–6) | 2 (0–4) | < 0.001 |
| Need for SOT, N (%) | 106 (78.5) | 29 (21.5) | 0.010 |
| SOT, Days (IQR) | 2.0 (1–3.2) | 2.0 (1.0–2.0) | 0.257 |
| Need for HFNC, N (%) | 106 (51.7) | 33 (39.7) | 0.066 |
| HFNC, Days (IQR) | 3 (2.0–4.5) | 3 (2.0–5.0) | 0.579 |
| Need for HcPAP, N (%) | 44 (21.5) | 8 (15.4) | 0.018 |
| HcPAP, Days (IQR) | 3 (2.25–4) | 3 (1.25–3.75) | 0.316 |
| Need for IMV, N (%) | 6 (2.9) | 2 (2.4) | 0.809 |
| IMV, Days (IQR) | 5 (3.75–6.25) | 4 (4.0–4.0) | 0.643 |